Seelos Therapeutics to Participate in 33rd Annual National MPS Society Family Conference
2019年12月13日 - 10:30PM
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, today
announced that it will participate in the 33rd Annual National MPS
Society Family Conference, December 19-21 in Orlando, FL.
“Our company’s attendance and sponsored booth at this year’s
National MPS Society Family Conference will provide us access to
meet families of patients who have been living with these
devastating MPS diseases as well as newly diagnosed patients’
families,” said Raj Mehra, Ph.D., Chairman and CEO of Seelos
Therapeutics, “We hope that through our studies with SLS-005 we can
offer some hope and possibly a potential treatment for those with
Sanfilippo syndrome.” Seelos plans to study SLS-005 (trehalose) in
Mucopolysaccharidosis Type III (MPS III), also known as Sanfilippo
Syndrome. The clinical trial for SLS-005 is a combined Phase
IIb/III, multicenter study designed to assess safety, tolerability
and efficacy of trehalose IV in Sanfilippo A and B based on
functional outcomes, biomarkers, neuro-cognitive assessments and
quality of life measurements. Additionally, Seelos intends to
expand inclusion of Sanfilippo type C and D patients as well as
type A and B patients who do not meet the trial entry criteria into
a separate expanded patient access study. About National
MPS Society The National MPS Society and its members raise
money to provide student fellowships and fund research projects.
They participate in and host technical conferences that allow
researchers to collaborate and discuss their findings. They
collaborate with other lysosomal storage disease (LSD) patient
support groups and family research foundations to fund research.
Their family support programs range from continuing education
scholarships to medical travel expense assistance, and they publish
a series of resource guides dealing with specific syndromes and
treatments that can help families learn more about the MPS
diagnosis and the future to come. Their digital newsletter,
Courage, features stories on research and medical advances, family
news, upcoming events, advocacy opportunities and fundraising
efforts. Each year, they hold a conference at different locations,
enabling families to meet and learn more about their disease. They
also provide emotional support to all those affected by MPS.
https://mpssociety.org/about/ About
Trehalose Trehalose is a low molecular weight disaccharide
(.342 kDa) that crosses the blood brain barrier, stabilizes
proteins, and importantly activates autophagy which is the process
that clears material from cells. In several animal models of
diseases, associated with abnormal cellular protein aggregation or
storage of pathologic material, it has been shown to reduce
aggregation of misfolded proteins and reduce accumulation of
pathologic material. Trehalose activates autophagy through the
activation of Transcription Factor EB (TFEB), a key factor in
lysosomal and autophagy gene expression. Activation of TFEB is an
emerging therapeutic target for a number of diseases with
pathologic accumulation of storage material. Forward
Looking Statements Statements made in this press release,
which are not historical in nature, constitute forward-looking
statements for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. These statements include,
among others, those regarding our plans to study SLS-005
(trehalose) in MPS III, also known as Sanfilippo Syndrome, and our
intention to expand inclusion of Sanfilippo type C and D patients
as well as type A and B patients who do not meet the trial entry
criteria into a separate expanded patient access study. These
statements are based on the company's current expectations and
beliefs and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements. Risks associated to
Seelos' business include, but are not limited to, the risk of not
successfully executing its clinical studies and not gaining
marketing approvals for our product candidates, the risks
associated with the implementation of a new business strategy, the
risks related to raising capital to fund our development plans and
ongoing operations, risks related to our current stock price, as
well as other factors expressed in Seelos' periodic filings with
the U.S. Securities and Exchange Commission, including its Annual
Report on Form 10-K and Quarterly Reports on Form
10-Q. Although we believe that the expectations reflected in
our forward-looking statements are reasonable, we do not know
whether our expectations will prove correct. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof, even if subsequently made
available by us on our website or otherwise. We do not undertake
any obligation to update, amend or clarify these forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required under applicable securities
laws. Contact Information: Anthony Marciano Head of Corporate
Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL) 300 Park
Ave., 12th FlNew York, NY 10022 (646)
293-2136anthony.marciano@seelostx.comhttps://seelostherapeutics.com/https://twitter.com/seelostxhttps://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 6 2024 まで 7 2024
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 7 2023 まで 7 2024